Warner Chilcott Plans $750M HY Offer

Sheahan, Matthew
August 2010
High Yield Report;8/16/2010, Vol. 21 Issue 33, p29
The article reports on the plans of specialty pharmaceutical provider Warner Chilcott to sell 750 million U.S. dollars in junk bonds to help pay a 2.14 billion U.S. dollar dividend to shareholders.


Related Articles

  • Warner Chilcott Makes $500M Add-On Offer. Sheahan, Matthew // High Yield Report;9/27/2010, Vol. 21 Issue 39, p33 

    The article reports on an add-on junk bond of 500 million U.S. dollars issued by Ardee, Ireland-based pharmaceutical firm Warner Chilcott.

  • Warner Chilcott Plans $750M HY Offer. Sheahan, Matthew // Mergers & Acquisitions Report;8/16/2010, Vol. 23 Issue 33, p16 

    The article focuses on the plan of Warner Chilcott to sell junk bonds worth about 750 million U.S. dollars in order to help in granting a 2.14 billion dollars dividend to shareholders.

  • New name.  // Drug Topics;7/22/96, Vol. 140 Issue 14, p21 

    Announces the change in the name of Nale Laboratories PLC which is now known as Warner Chilcott Laboratories PLC.

  • Warner Chilcott Prices Add-On Bonds Above Par. Sheahan, Matthew // High Yield Report;10/4/2010, Vol. 21 Issue 40, p1 

    This article reports on the issuance of add-on bonds by Irish pharmaceutical company Warner Chilcott in an offering to help fund an acquisition.

  • Warner Chilcott Plans to Offer $600M in Loans. Bisbey, Allison // High Yield Report;8/13/2012, p12 

    The article reports on the plan of specialty pharmaceutical company Warner Chilcott to issue two new, 300 million U.S. dollar term loans to help fund a special dividend to shareholders.

  • Lo Loestrin FE contraceptive.  // Monthly Prescribing Reference;Dec2010, Vol. 26 Issue 12, pA18 

    The article reports on the approval of Lo Loestrin Fe, norethindrone acetate and ethinyl estradiol tables to prevent pregnancy in women, from Warner Chilcott PLC.

  • Warner Chilcott Kicks Off $3.25 Billion Refi. Kellerhals, Richard // High Yield Report;3/7/2011, Vol. 22 Issue 10, p11 

    The article reports on a refinancing debt launched by Warner Chilcott.

  • SWOT ANALYSIS.  // Warner Chilcott Ltd. SWOT Analysis;Jun2011, p1 

    The article reports on the strengths, weaknesses, opportunities and threats (SWOT) analysis of pharmaceutical company Warner Chilcott Public Ltd. Co. (WC). WC products are focused on medications for gastroenterology, women's healthcare, and dermatology, with core products such as Actonel and...

  • Warner Chilcott's P&G Buy Was a Balm for PE. Holman, Kelly // Investment Dealers' Digest;1/29/2010, Vol. 76 Issue 4, p23 

    The article announces the Warner Chilcott Ltd. acquisition of Procter & Gamble Co. global pharmaceuticals business was recognized as Private-Equity Deal of the Year from "Investment Dealers' Digest."


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics